IDC: Increasing demand for mobile health IT products

The importance of a clinical team’s ability to quickly access and communicate information has led to increased use of mobile technologies, but recent IDC Health Insights research suggested a demand for more advanced mobile technologies and predicted a growing market for products that service this need.

“Increasingly, clinicians are turning to a range of mobile point-of-care (MPOC) devices, such as purpose-built devices, smartphones and tablets to access clinical information systems and document care at the patient bedside or in the exam room,” authors of the December report wrote.

Respondents to an IDC Health Insights survey reported using an average of 6.4 different mobile devices on a daily basis. Forty-two percent reported high to very high adoption rates among their organization’s physicians and 86 percent predicted increased adoption rates in the next 12 to 24 months.

Laptops, tablets and workstations on wheels were the most widely used mobile technologies among survey respondents with 84 percent reporting laptop use, 56 percent reporting PC tablet use and 54 percent reporting workstations on wheels use.

According to the survey results, the top obstacles to mobile technology deployment were data security, with 32 percent of respondents calling it a challenge, and cost, also with 32 percent calling it a challenge.

Based on the survey results, the Framingham, Mass.-based market research firm predicted that spending on mobile technologies will increase through at least 2015, but that healthcare organizations will focus spending on software, infrastructure upgrades and securing data, rather than on purchasing new hardware.

The IDC Health Insights report also indicated that healthcare organizations will attempt to resolve issues specific to individually owned devices, such as smartphones, that are not subject to institutional security policies even though they may be used for professional, as well as personal, purposes.

IDC Health Insight’s research report was based on the results of a web-based survey of clinical mobility decision-makers from 50 hospitals located in either the U.S. or Western Europe. The report was sponsored by Intel, a Santa Clara, Calif.-based computer manufacturer.

The report is available here.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.